Combining local therapies with systemic treatment for certain cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 pragmatic study evaluates the effectiveness of adding locally ablative therapies to ongoing systemic therapy for patients with oligo-progressive solid tumors, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. The primary goal is to assess disease control at three months, defined as the ability to continue systemic therapy without changes or permanent discontinuation after receiving local ablative treatment. Participants will receive either stereotactic ablative radiotherapy or interventional radiology ablation therapy, based on the discretion of their treating physicians, and will be monitored for up to five years. The study aims to determine the time to treatment failure following the addition of these local therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies:

   1. Cohort A: prostate cancer
   2. Cohort B: urothelial carcinoma
   3. Cohort C: renal cell carcinoma
2. Provision of signed and dated informed consent form.
3. Stated willingness to comply with all study procedures and availability for the duration of the study.
4. Age ≥18 years at time of consent.
5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.
6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\]
7. ≤ 5 progressing or new metastatic lesions.
8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.

Exclusion Criteria:

1. Medical comorbidities precluding locally ablative therapies.
2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.
3. Progressing intracranial lesions.

Where it's running

• University of California, Davis
  Sacramento, California, United States Recruiting

Study contacts

• Principal investigator: Mamta Parikh, MD, MS — University of California, Davis
• Study coordinator: Office of Clinical Research
• Email: OCRReferral@health.ucdavis.edu
• Phone: 916-382-6970

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating QXL138AM for patients with advanced solid tumors and multiple myeloma

  This study is testing a new drug called QXL138AM to see if it can safely help people with advanced solid tumors and multiple myeloma.

  Recruiting at 11 sites Phase 1 Nammi Therapeutics Inc · Los Angeles, California and 10 other locations · NCT06582017

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• DCC-2812 in advanced kidney, bladder, and castration-resistant prostate cancers

  This trial will test whether the oral drug DCC-2812 is safe and shows early signs of benefit for people with advanced kidney (renal cell), bladder (urothelial), or castration-resistant prostate cancer.

  Recruiting at 8 sites Phase 1 Deciphera Pharmaceuticals, LLC · Boston, Massachusetts and 7 other locations · NCT06966024

• Evaluating MT-4561 in Patients with Advanced Solid Tumors

  This study is testing a new drug called MT-4561 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 6 sites Phase 1/2 Tanabe Pharma America, Inc. · Los Angeles, California and 5 other locations · NCT06943521

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.